Molecular understanding of hyperglycemia's adverse effects for diabetic complications.

Diabetic complications are the major cause of morbidity and mortality in persons with diabetes. Chronic hyperglycemia is a major initiator of diabetic microvascular complications (eg, retinopathy, neuropathy, nephropathy). Glucose processing uses a variety of diverse metabolic pathways; hence, chronic hyperglycemia can induce multiple cellular changes leading to complications. Several predominant well-researched theories have been proposed to explain how hyperglycemia can produce the neural and vascular derangements that are hallmarks of diabetes. These theories can be separated into those that emphasize the toxic effects of hyperglycemia and its pathophysiological derivatives (such as oxidants, hyperosmolarity, or glycation products) on tissues directly and those that ascribe pathophysiological importance to a sustained alteration in cell signaling pathways (such as changes in phospholipids or kinases) induced by the products of glucose metabolism. This article summarizes these theories and the potential therapeutic interventions that may prevent diabetic complications in the presence of hyperglycemia, control of which is often difficult with current therapeutic options.

[1]  A J Adams,et al.  Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. , 1999, Investigative ophthalmology & visual science.

[2]  H. Bohlen,et al.  Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. , 2001, American journal of physiology. Heart and circulatory physiology.

[3]  F. Ziyadeh The extracellular matrix in diabetic nephropathy. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  Y. Akagi,et al.  Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. , 1990, Archives of ophthalmology.

[5]  V. Monnier,et al.  Accelerated age-related browning of human collagen in diabetes mellitus. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. King,et al.  Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus , 1997, Journal of Molecular Medicine.

[7]  B. Tesfamariam Free radicals in diabetic endothelial cell dysfunction. , 1994, Free radical biology & medicine.

[8]  R. Kikkawa,et al.  Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. , 2001, Diabetes care.

[9]  E. Feldman,et al.  Complications: Neuropathy, Pathogenetic Considerations , 1992, Diabetes Care.

[10]  G. Schmid-Schönbein,et al.  Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. , 1991, The American journal of pathology.

[11]  S. Bursell,et al.  Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.

[12]  S. Tesfaye,et al.  Vascular factors in diabetic neuropathy , 1994, Diabetologia.

[13]  S. Shatadal,et al.  Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells , 2000 .

[14]  Y. Kaneda,et al.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage , 2000, Nature.

[15]  A. Schmidt,et al.  RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes , 2000, Trends in Endocrinology & Metabolism.

[16]  E. Kohner,et al.  Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. , 1999, Cellular and molecular biology.

[17]  T. Cruz,et al.  Involvement of Reactive Oxygen Species in Cytokine and Growth Factor Induction of c-fos Expression in Chondrocytes(*) , 1995, The Journal of Biological Chemistry.

[18]  Y. Hinokio,et al.  Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. , 1999, Diabetes research and clinical practice.

[19]  V. Ferrans,et al.  Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction , 1995, Science.

[20]  S. Devaraj,et al.  Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. , 2001, Clinical chemistry.

[21]  G. King,et al.  d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity. , 1999, Diabetes research and clinical practice.

[22]  J. Tang,et al.  Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. , 2001, Diabetes.

[23]  L. Aiello,et al.  High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. , 1999, Diabetes care.

[24]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[25]  Hidehiro Ishii,et al.  Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.

[26]  L. Aiello,et al.  Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. , 1997, Diabetes/metabolism reviews.

[27]  J. Lunec,et al.  Vitamin C metabolites and microangiopathy in diabetes mellitus. , 1987, Diabetes research.

[28]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[29]  S. Bursell,et al.  Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. , 1993, The American journal of physiology.

[30]  V. Natarajan,et al.  Hydroperoxide-induced diacylglycerol formation and protein kinase C activation in vascular endothelial cells. , 1993, Archives of biochemistry and biophysics.

[31]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[32]  R. Myers,et al.  Galactose neuropathy: Impact of chronic endoneurial edema on nerve blood flow , 1984, Annals of neurology.

[33]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[34]  S. Basili,et al.  Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. , 1997, Metabolism: clinical and experimental.

[35]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[36]  S. Kawashima,et al.  Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus , 1999, The British journal of ophthalmology.

[37]  P. Low,et al.  Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy , 1995, Experimental Neurology.

[38]  C. Whiteside,et al.  Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells. , 1998, Diabetes.

[39]  A. Samii,et al.  Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats , 1999, Neuroscience Letters.

[40]  P. Dyck,et al.  Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Szabó,et al.  Rapid Reversal of the Diabetic Endothelial Dysfunction by Pharmacological Inhibition of Poly(ADP-Ribose) Polymerase , 2001, Circulation research.

[42]  Norman Fleischer,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .

[43]  S. Srinivasan,et al.  Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. , 2000, Diabetes.

[44]  H. Brady,et al.  Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. , 2000, Kidney international.

[45]  K. Moon,et al.  Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. , 2001, The Journal of laboratory and clinical medicine.

[46]  J. Baynes,et al.  Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.

[47]  B. Gallacher,et al.  Glucose-Induced Protein Kinase C Activation Regulates Vascular Permeability Factor mRNA Expression and Peptide Production by Human Vascular Smooth Muscle Cells In Vitro , 1997, Diabetes.

[48]  S. Bain,et al.  Genetics of diabetic nephropathy. , 2001, Best practice & research. Clinical endocrinology & metabolism.

[49]  J. Crowley,et al.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. , 1999, The Journal of clinical investigation.

[50]  H. Tritschler,et al.  Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy , 1995, Diabetes Care.

[51]  J. Baynes,et al.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.

[52]  E M Kohner,et al.  Role of Blood Flow and Impaired Autoregulation in the Pathogenesis of Diabetic Retinopathy , 1995, Diabetes.

[53]  P. Durrington,et al.  Paraoxonase and coronary heart disease. , 1998, Atherosclerosis. Supplements.

[54]  J. Williamson,et al.  Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. , 2001 .

[55]  G. King,et al.  Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. , 2000, Circulation.

[56]  J. Kinoshita Mechanisms initiating cataract formation. Proctor Lecture. , 1974, Investigative ophthalmology.

[57]  M. Cotter,et al.  Effects of diabetes on reactivity of sciatic vasa nervorum in rats. , 1997, Journal of diabetes and its complications.

[58]  N. Hotta,et al.  A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. , 1999, Diabetes.

[59]  K. Gabbay,et al.  Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. , 1975, Annual review of medicine.

[60]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[61]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[62]  H. Ha,et al.  Reactive oxygen species as glucose signaling molecules in mesangial cells cultured under high glucose. , 2000, Kidney international. Supplement.

[63]  V. Gopalakrishnan,et al.  Endothelin: emerging role in diabetic vascular complications , 1999, Diabetologia.

[64]  A. Veves,et al.  Endoneurial localisation of microvascular damage in human diabetic neuropathy , 1993, Diabetologia.

[65]  A. Cerami,et al.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.

[66]  L. Dekker,et al.  Protein kinase C-beta contributes to NADPH oxidase activation in neutrophils. , 2000, The Biochemical journal.

[67]  D. Tomlinson Mitogen-activated protein kinases as glucose transducers for diabetic complications , 1999, Diabetologia.

[68]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[69]  H. Lum,et al.  Oxidant stress and endothelial cell dysfunction. , 2001, American journal of physiology. Cell physiology.

[70]  E. Ritz,et al.  Nephropathy in patients with type 2 diabetes mellitus. , 1999, The New England journal of medicine.

[71]  M. Meier,et al.  Protein kinase C activation and its pharmacological inhibition in vascular disease , 2000, Vascular medicine.

[72]  R. Danis,et al.  Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. , 1998, Investigative ophthalmology & visual science.

[73]  J. Baynes Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[74]  K. Sugimoto,et al.  Diabetic neuropathy – a continuing enigma , 2000, Diabetes/metabolism research and reviews.

[75]  E. Boyko,et al.  Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. , 1999, Diabetes care.

[76]  M. Steffes,et al.  Effects of Sorbinil on Glomerular Structure and Function in Long-Term–Diabetic Rats , 1989, Diabetes.

[77]  R. Klein,et al.  The Wisconsin epidemiological study of diabetic retinopathy: a review. , 1989, Diabetes/metabolism reviews.

[78]  E. Schiffrin,et al.  Vascular biology of endothelin. , 1998, Journal of cardiovascular pharmacology.

[79]  H. Utsumi,et al.  High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.

[80]  S. Bursell,et al.  Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. , 1996, Investigative ophthalmology & visual science.

[81]  J. Kreisberg,et al.  The glomerular mesangium in diabetes mellitus. , 1993, Kidney international.

[82]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[83]  N. Hotta,et al.  Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. , 1996, Biochemical and biophysical research communications.

[84]  G. King,et al.  Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[85]  G. Dibona,et al.  Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. , 2000, Diabetes.

[86]  W. J. Litchy,et al.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population‐based cohort , 1993, Neurology.

[87]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[88]  W. Benedict,et al.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. , 1999, Science.

[89]  Y. Akai,et al.  Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus , 1996 .

[90]  G. King,et al.  Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. , 1997, The Journal of clinical investigation.

[91]  L. Aiello,et al.  Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. , 1996, The Journal of clinical investigation.

[92]  A. Kashiwagi,et al.  Impaired Activation of Glucose Oxidation and NADPH Supply in Human Endothelial Cells Exposed to H2O2 in High-Glucose Medium , 1995, Diabetes.

[93]  A. Malik,et al.  Protein kinase C β1 overexpression augments phorbol ester‐induced increase in endothelial permeability , 1996, Journal of cellular physiology.

[94]  N. Holbrook,et al.  Oxidative Stress-induced Phospholipase C-γ1 Activation Enhances Cell Survival* , 2001, The Journal of Biological Chemistry.

[95]  P. Campochiaro,et al.  Retinal and choroidal neovascularization , 2000, Journal of cellular physiology.

[96]  E. Schulze-Lohoff,et al.  Regulation of mesangial cell function by vasodilatory signaling molecules. , 2001, Cardiovascular research.

[97]  L. Aiello,et al.  Diabetic eye disease. , 1996, Endocrinology and metabolism clinics of North America.

[98]  P. Parker,et al.  The extended protein kinase C superfamily. , 1998, The Biochemical journal.

[99]  S. Jain,et al.  Effect of glycemic control, race (white versus black), and duration of diabetes on reduced glutathione content in erythrocytes of diabetic patients. , 1994, Metabolism: clinical and experimental.

[100]  K. Sharma,et al.  Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. , 1994, The Journal of clinical investigation.

[101]  A. Bird,et al.  The genetics of complex ophthalmic disorders. , 1996, The British journal of ophthalmology.

[102]  M. Cooper,et al.  Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. , 1999, Diabetes.

[103]  M. Matsumura,et al.  Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. , 2001, American journal of ophthalmology.

[104]  B. Tesfamariam Selective impairment of endothelium‐dependent relaxations by prostaglandin endoperoxide , 1994, Journal of hypertension.

[105]  R. Griffey,et al.  Diabetic neuropathy. Structural analysis of nerve hydration by magnetic resonance spectroscopy. , 1988, Journal of the American Medical Association (JAMA).

[106]  A. Krolewski,et al.  Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in Type I diabetes mellitus , 2000, Diabetologia.

[107]  A. Reddi,et al.  Transforming Growth Factor-β1 Enhances Glomerular Collagen Synthesis in Diabetic Rats , 1993, Diabetes.

[108]  N. Perico,et al.  Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats , 1992, Diabetes.

[109]  L. Oberley Free radicals and diabetes. , 1988, Free radical biology & medicine.

[110]  E. Schleicher,et al.  Structural and functional changes in diabetic glomerulopathy. , 1996, Kidney & Blood Pressure Research.

[111]  T. Hohman,et al.  Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. , 1989, Investigative ophthalmology & visual science.

[112]  A. Windebank,et al.  Capillary number and percentage closed in human diabetic sural nerve. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Isner,et al.  Reversal of experimental diabetic neuropathy by VEGF gene transfer. , 2001, The Journal of clinical investigation.

[114]  F. DeRubertis,et al.  Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. , 2001, Diabetes.

[115]  S. Tesfaye,et al.  Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy , 2001, Diabetologia.

[116]  G. Paolisso,et al.  Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.

[117]  F. DeRubertis,et al.  Antioxidant inhibition of protein kinase C-signaled increases in transforming growth factor-beta in mesangial cells. , 1997, Metabolism: clinical and experimental.

[118]  Y. Nishizuka Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. , 1992, Science.

[119]  D. Yue,et al.  The Effect of Aldose Reductase Inhibition on Motor Nerve Conduction Velocity in Diabetic Rats , 1982, Diabetes.